ARMONK, N.Y. AND MILWAUKEE, Wis. – 02 Jun 2016: IBM (NYSE: IBM) today announced Froedtert & the Medical College of Wisconsin Cancer Network will adopt Watson cognitive computing to help match cancer patients with clinical trials. The Froedtert & MCW Cancer Network is the first in Wisconsin and among the first cancer programs in the nation to use Watson for Clinical Trial Matching. The matching program is slated to begin this fall.

Clinical trials are the gold standard in medical evidence and crucial for developing new treatment options for the 13.8 million Americans currently battling cancer. Finding and enrolling eligible patients in clinical trials is difficult, and less than five percent of cancer patients are participating in a trial. Watson for Clinical Trial Matching is designed to quickly complete the data-intensive process of matching patients with clinical trials, and provide doctors the information they need to advise their patients about relevant studies. For example, after a clinician submits a patient’s unique health information, Watson will analyze the patient’s data against clinical trial databases to provide clinicians with information regarding a patient’s eligibility for a specific trial.

Read the full article from IBM here: